Review
. 2016 Feb;9().
doi: 10.2147/PGPM.S56055.

Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives

Meagan B Myers 1 
Affiliations
  • PMID: 26858530
  •     71 References
  •     9 citations

Abstract

Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.

Keywords: HER2; estrogen receptor; in vitro diagnostics; multigene assay; precision medicine.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Ana M Gonzalez-Angulo, Jennifer K Litton, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884543    Free PMC article.
Highly Cited.
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.
Torsten Nielsen, Brett Wallden, +7 authors, James Storhoff.
BMC Cancer, 2014 Mar 15; 14. PMID: 24625003    Free PMC article.
Highly Cited.
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J M Harvey, G M Clark, C K Osborne, D C Allred.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334533
Highly Cited.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, +12 authors, EMILIA Study Group.
N Engl J Med, 2012 Oct 02; 367(19). PMID: 23020162    Free PMC article.
Highly Cited.
Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.
Soonmyung Paik.
Oncologist, 2007 Jul 03; 12(6). PMID: 17602054
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Martin Filipits, Torsten O Nielsen, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Clin Cancer Res, 2014 Feb 13; 20(5). PMID: 24520097
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.
John Hornberger, Michael D Alvarado, +3 authors, William J Gradishar.
J Natl Cancer Inst, 2012 Jul 07; 104(14). PMID: 22767204
Systematic Review.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
G M Clark, C K Osborne, W L McGuire.
J Clin Oncol, 1984 Oct 01; 2(10). PMID: 6491696
Highly Cited.
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
Viviana Galimberti, Bernard F Cole, +25 authors, International Breast Cancer Study Group Trial 23-01 investigators.
Lancet Oncol, 2013 Mar 16; 14(4). PMID: 23491275    Free PMC article.
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
Arch Pathol Lab Med, 2013 Oct 09; 138(2). PMID: 24099077    Free PMC article.
Highly Cited.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, +3 authors, W L McGuire.
Science, 1987 Jan 09; 235(4785). PMID: 3798106
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
The molecular portraits of breast tumors are conserved across microarray platforms.
Zhiyuan Hu, Cheng Fan, +28 authors, Charles M Perou.
BMC Genomics, 2006 Apr 29; 7. PMID: 16643655    Free PMC article.
Highly Cited.
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
M Gnant, M Filipits, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Ann Oncol, 2013 Dec 19; 25(2). PMID: 24347518
Highly Cited.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
G Pauletti, W Godolphin, M F Press, D J Slamon.
Oncogene, 1996 Jul 04; 13(1). PMID: 8700555
Highly Cited.
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
B Fisher, C Redmond, +7 authors, J Wittliff.
J Clin Oncol, 1983 Apr 01; 1(4). PMID: 6366135
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Trastuzumab--mechanism of action and use in clinical practice.
Clifford A Hudis.
N Engl J Med, 2007 Jul 06; 357(1). PMID: 17611206
Highly Cited. Review.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Robert W Carlson, Elizabeth Brown, +13 authors, National Comprehensive Cancer Network.
J Natl Compr Canc Netw, 2006 Mar 02; 4 Suppl 1. PMID: 16507275
Review.
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Ron Bose, Shyam M Kavuri, +11 authors, Matthew J Ellis.
Cancer Discov, 2012 Dec 12; 3(2). PMID: 23220880    Free PMC article.
Highly Cited.
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Christos Sotiriou, Soek-Ying Neo, +7 authors, Edison T Liu.
Proc Natl Acad Sci U S A, 2003 Aug 15; 100(18). PMID: 12917485    Free PMC article.
Highly Cited.
Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.
Emad A Rakha, Maysa E El-Sayed, +5 authors, Ian O Ellis.
J Clin Oncol, 2008 May 21; 26(19). PMID: 18490649
Highly Cited.
Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.
H J Lerner, P R Band, L Israel, B S Leung.
Cancer Treat Rep, 1976 Oct 01; 60(10). PMID: 798626
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, +12 authors, CLEOPATRA Study Group.
N Engl J Med, 2011 Dec 14; 366(2). PMID: 22149875    Free PMC article.
Highly Cited.
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series.
M J Rodrigues, J Peron, +7 authors, P H Cottu.
Ann Oncol, 2012 Oct 30; 24(4). PMID: 23104720
The basic biology of HER2.
I Rubin, Y Yarden.
Ann Oncol, 2001 Aug 28; 12 Suppl 1. PMID: 11521719
Review.
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
G Valabrega, F Montemurro, M Aglietta.
Ann Oncol, 2007 Jan 19; 18(6). PMID: 17229773
Highly Cited. Review.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, +17 authors, Jose Baselga.
Lancet Oncol, 2014 Mar 25; 15(6). PMID: 24657003
Highly Cited.
Untangling the ErbB signalling network.
Y Yarden, M X Sliwkowski.
Nat Rev Mol Cell Biol, 2001 Mar 17; 2(2). PMID: 11252954
Highly Cited. Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Treatment of primary breast cancer with chemotherapy and tamoxifen.
B Fisher, C Redmond, +20 authors, H Shibata.
N Engl J Med, 1981 Jul 02; 305(1). PMID: 7015139
Highly Cited.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
B Fisher, J Costantino, +7 authors, E R Fisher.
N Engl J Med, 1989 Feb 23; 320(8). PMID: 2644532
Highly Cited.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns.
Abigail S Caudle, Kelly K Hunt, +9 authors, Elizabeth A Mittendorf.
Ann Surg Oncol, 2012 Aug 01; 19(10). PMID: 22847123    Free PMC article.
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
D Craig Allred, Robert W Carlson, +11 authors, Antonio C Wolff.
J Natl Compr Canc Netw, 2009 Dec 03; 7 Suppl 6. PMID: 19755043
Review.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
D C Tormey, R Gray, H C Falkson.
J Natl Cancer Inst, 1996 Dec 18; 88(24). PMID: 8961972
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Vanya Van Belle, Ben Van Calster, +17 authors, Patrick Neven.
J Clin Oncol, 2010 Aug 18; 28(27). PMID: 20713855
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
Heather L McArthur, Kathleen M Mahoney, +5 authors, Clifford A Hudis.
Cancer, 2011 Jun 18; 117(24). PMID: 21681735
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.
Harold J Burstein, Sarah Temin, +10 authors, Jennifer J Griggs.
J Clin Oncol, 2014 May 29; 32(21). PMID: 24868023    Free PMC article.
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.
Gary H Lyman, Sarah Temin, +12 authors, American Society of Clinical Oncology Clinical Practice.
J Clin Oncol, 2014 Mar 26; 32(13). PMID: 24663048
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, +15 authors, David Cameron.
N Engl J Med, 2006 Dec 29; 355(26). PMID: 17192538
Highly Cited.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
J Clin Oncol, 2013 Oct 09; 31(31). PMID: 24101045
Highly Cited.
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, +13 authors, Lajos Pusztai.
Clin Cancer Res, 2005 Aug 24; 11(16). PMID: 16115903
Highly Cited.
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
Ralf Landgraf.
Breast Cancer Res, 2007 Feb 06; 9(1). PMID: 17274834    Free PMC article.
Review.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
Ivana Sestak, Jack Cuzick, +8 authors, Michael Gnant.
J Clin Oncol, 2014 Oct 22; 33(8). PMID: 25332252
Highly Cited.
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Neil L Spector, Kimberly L Blackwell.
J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884552
Highly Cited. Review.
Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy.
Ioannis A Voutsadakis, Silvana Spadafora.
World J Clin Oncol, 2015 Feb 11; 6(1). PMID: 25667909    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Keith T Schmidt, Cindy H Chau, Douglas K Price, William D Figg.
J Clin Pharmacol, 2016 May 21; 56(12). PMID: 27197880    Free PMC article.
Review.
Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions.
María Vallet-Regí, Miguel Manzano, +3 authors, Lodovico Balducci.
Oncologist, 2017 Feb 22; 22(3). PMID: 28220025    Free PMC article.
Review.
Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
Beate Jahn, Ursula Rochau, +9 authors, Uwe Siebert.
BMC Cancer, 2017 Oct 19; 17(1). PMID: 29037213    Free PMC article.
Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches.
Laura Maciejko, Munisha Smalley, Aaron Goldman.
J Mol Biomark Diagn, 2017 Dec 30; 8(5). PMID: 29285416    Free PMC article.
Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.
Emily B Ehlerding, Piotr Grodzinski, Weibo Cai, Christina H Liu.
ACS Nano, 2018 Feb 21; 12(3). PMID: 29462554    Free PMC article.
Review.
Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.
David Jonathan Duncan, Michel Erminio Vandenberghe, Marietta Louise Juanita Scott, Craig Barker.
PLoS One, 2019 Oct 16; 14(10). PMID: 31613934    Free PMC article.
Precision medicine in cardiology.
Elliott M Antman, Joseph Loscalzo.
Nat Rev Cardiol, 2016 Jul 01; 13(10). PMID: 27356875
Highly Cited. Review.
Clinical target sequencing for precision medicine of breast cancer.
Junko Tsuchida, Jami Rothman, +3 authors, Toshifumi Wakai.
Int J Clin Oncol, 2019 Jan 04; 24(2). PMID: 30604156
Review.
Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
Meagan B Myers, Karen L McKim, +2 authors, Barbara L Parsons.
Int J Mol Sci, 2019 Mar 01; 20(5). PMID: 30813596    Free PMC article.